Umlaut (Biotechnology) Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $3.49M

  • Investors
  • 5

Umlaut (Biotechnology) General Information

Description

Developer of RNA-based therapeutics designed to target cancer and inflammatory diseases by modulating RNA modifications. The company offers small molecule approaches focused on tRNA modification and regulation of cellular signaling pathways, enabling healthcare and research communities to address disease progression beyond traditional protein-targeting methods.

Contact Information

Website
www.umlaut.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Nikola-Tesla-Strasse 1
  • 69124 Heidelberg
  • Germany
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences, Oncology
Corporate Office
  • Nikola-Tesla-Strasse 1
  • 69124 Heidelberg
  • Germany

Umlaut (Biotechnology) Timeline

20252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Umlaut (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 23-Mar-2026 $3.49M Completed Generating Revenue
1. Early Stage VC 08-Jul-2024 Completed Generating Revenue
To view Umlaut (Biotechnology)’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Umlaut (Biotechnology) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Umlaut (Biotechnology) Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
BaseLaunch Accelerator/Incubator Minority
High-Tech Gründerfonds Venture Capital Minority
L-Bank Venture Capital Minority
LBBW Venture Capital Corporate Venture Capital Minority
Mission BioCapital Venture Capital Minority
To view Umlaut (Biotechnology)’s complete investors history, request access »

Ready to get started?

Request a free trial

Umlaut (Biotechnology) FAQs

  • When was Umlaut (Biotechnology) founded?

    Umlaut (Biotechnology) was founded in 2024.

  • Where is Umlaut (Biotechnology) headquartered?

    Umlaut (Biotechnology) is headquartered in Heidelberg, Germany.

  • What is the size of Umlaut (Biotechnology)?

    Umlaut (Biotechnology) has 4 total employees.

  • What industry is Umlaut (Biotechnology) in?

    Umlaut (Biotechnology)’s primary industry is Biotechnology.

  • Is Umlaut (Biotechnology) a private or public company?

    Umlaut (Biotechnology) is a Private company.

  • What is Umlaut (Biotechnology)’s current revenue?

    The current revenue for Umlaut (Biotechnology) is .

  • How much funding has Umlaut (Biotechnology) raised over time?

    Umlaut (Biotechnology) has raised $3.49M.

  • Who are Umlaut (Biotechnology)’s investors?

    BaseLaunch, High-Tech Gründerfonds, L-Bank, LBBW Venture Capital, and Mission BioCapital have invested in Umlaut (Biotechnology).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process